ID
30896
Description
Study part: Administrative Data 2 (RANDOMISATION NUMBER (Rand), REGIMEN (Regimen)- Day 1,SUBJECT IDENTIFICATION (Subj ID),INVESTIGATIONAL PRODUCT (Dose) – Day 1-14 ). A phase 1 single-masked, randomized (with respect to placebo), placebo-controlled, parallel-group, dose-rising study to evaluate the safety, tolerability and pharmacokinetics of repeat oral doses of GW786034 in elderly healthy volunteers. Trade Name: Votrient. Clinical Study ID: MD1103367.
Keywords
Versions (1)
- 7/2/18 7/2/18 -
Copyright Holder
GlaxoSmithKline
Uploaded on
July 2, 2018
DOI
To request one please log in.
License
Creative Commons BY-NC 3.0
Model comments :
You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.
Itemgroup comments for :
Item comments for :
In order to download data models you must be logged in. Please log in or register for free.
Administrative Data 2 Pazopanib Macular Degeneration MD1103367
Administrative Data 2
- StudyEvent: ODM
Description
REGIMEN (Regimen)
Alias
- UMLS CUI-1
- C1276413
- UMLS CUI-2
- C0013227
Description
SUBJECT IDENTIFICATION (Subj ID)
Alias
- UMLS CUI-1
- C2348585
Description
INVESTIGATIONAL PRODUCT (Dose)
Alias
- UMLS CUI-1
- C0304229
- UMLS CUI-2
- C0178602
Similar models
Administrative Data 2
- StudyEvent: ODM
C0237753 (UMLS CUI-2)
C0237753 (UMLS CUI [1,2])
C0034656 (UMLS CUI [1,2])
C0178602 (UMLS CUI-2)